Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and...
FORNEBU, Norway, Jan. 16, 2025 /PRNewswire/ -- Reference is made to the announcement by Aker Horizons ASA ("Aker Horizons" or the "Company") on 9 January...